The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Moderna Inc’s stock clocked out at $43.39, up 3.19% from its previous closing price of $42.05. In other words, the price has increased by $3.19 from its previous closing price. On the day, 5.08 million shares were traded. MRNA stock price reached its highest trading level at $43.46 during the session, while it also had its lowest trading level at $42.08.
Ratios:
To gain a deeper understanding of MRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Berenberg on November 19, 2024, initiated with a Hold rating and assigned the stock a target price of $42.
On November 18, 2024, HSBC Securities Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $58.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Underperform rating and target price of $40.Wolfe Research initiated its Underperform rating on November 15, 2024, with a $40 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Hoge Stephen sold 277 shares for $46.10 per share. The transaction valued at 12,771 led to the insider holds 1,443,248 shares of the business.
Hoge Stephen bought 277 shares of MRNA for $12,771 on Nov 11 ’24. On Oct 07 ’24, another insider, Mock James M, who serves as the Chief Financial Officer of the company, sold 715 shares for $60.12 each. As a result, the insider received 42,986 and left with 9,505 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 16697251840 and an Enterprise Value of 11185245184. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.40 while its Price-to-Book (P/B) ratio in mrq is 1.40. Its current Enterprise Value per Revenue stands at 2.201 whereas that against EBITDA is -4.735.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $35.80. The 50-Day Moving Average of the stock is -18.62%, while the 200-Day Moving Average is calculated to be -54.54%.
Shares Statistics:
It appears that MRNA traded 6.91M shares on average per day over the past three months and 12078310 shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 343.15M. Insiders hold about 10.83% of the company’s shares, while institutions hold 67.52% stake in the company. Shares short for MRNA as of 1731628800 were 39863421 with a Short Ratio of 5.77, compared to 1728950400 on 33260603. Therefore, it implies a Short% of Shares Outstanding of 39863421 and a Short% of Float of 13.63.
